Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-4915 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-4915 | EXPERIMENTAL | Participants will be administered a single dose of ALN-4195. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-4915 | DRUG | ALN-4915 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
Inclusion Criteria: * Is willing and able to complete all study assessments Exclusion Criteria: * Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN) * Has total bilirubin \>ULN * Has no history of invasive infection by an encapsulated organism * H...
ALN-4915 is an investigational small molecule developed by Alnylam Pharmaceuticals, Inc. It is in Phase 1 clinical development and is being studied in adult healthy volunteers. The specific disease indications it is intended to treat have not been disclosed.
ALN-4915 is being developed by Alnylam Pharmaceuticals, Inc., which trades on Nasdaq under the ticker ALNY. Alnylam is the sponsor of the Phase 1 study evaluating the compound in adult healthy volunteers.
ALN-4915 is in Phase 1 clinical development. It is investigational and is being evaluated in a single active study in adult healthy volunteers. No completed trials of ALN-4915 have been recorded.
ALN-4915 is being studied in trial NCT07535606, titled A Study to Evaluate ALN-4915 in Adult Healthy Volunteers. The Phase 1 trial is active but not recruiting, is placebo-controlled and double-blind, and is expected to enroll 36 participants in the United Kingdom.
The Phase 1 study of ALN-4915, NCT07535606, is a randomized, double-blind, placebo-controlled trial in adult healthy volunteers aged 18 years and older of all sexes. It is being conducted in the United Kingdom, has a planned enrollment of 36 participants, and is currently active but not recruiting.